CommercialDocumentationMedium impact
08.02.01c, Mirvetuximab soravtansine-gynx (Elahere®)
Independence Blue Cross·Oncology, Pharmacy·Pharmacy
Effective date
Jun 16, 2025
We identified it
Jun 19, 2026
Summary
Policy 08.02.01c establishes or updates medical necessity criteria for Mirvetuximab soravtansine-gynx (Elahere®), a pharmacy benefit medication. The billing team must ensure claims for this drug include proper documentation of medical necessity to support coverage determinations and avoid denials.
Action Required
By June 16, 2025: Billing team must implement medical necessity review process for all Elahere® (mirvetuximab soravtansine-gynx) claims billed under HCPCS code J9342. Coordinate with providers to ensure treatment documentation meets policy criteria before claim submission. Update billing system to flag J9342 claims for medical necessity validation. Route claims lacking required documentation back to clinical staff for supplementation. Failure to document medical necessity per policy will result in claim denials.